Repurposing itraconazole as a treatment for advanced prostate cancer: A noncomparative randomized phase ii trial in men with metastatic castration-resistant prostate cancer

Oncologist

Volumn 18, Issue 2, 2013, Pages 163-173

  Antonarakis, Emmanuel S ^a   Heath, Elisabeth I ^b   Smith, David C ^c   Rathkopf, Dana ^d   Blackford, Amanda L ^a   Danila, Daniel C ^d   King, Serina ^a   Frost, Anja ^a   Seun Ajiboye, A ^a   Zhao, Ming ^a   Mendonca, Janet ^a   Kachhap, Sushant K ^a   Rudek, Michelle A ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Hedgehog pathway; Itraconazole; Prostate cancer

Indexed keywords

ALDOSTERONE; ANDROGEN; CORTICOTROPIN; HYDROCORTISONE; ITRACONAZOLE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRANSCRIPTION FACTOR GLI1; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FOLLOW UP; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; HYPOKALEMIA; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; MASS SPECTROMETRY; METASTASIS; NAUSEA; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TASTE DISORDER; TREATMENT OUTCOME; URINARY DYSFUNCTION; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ITRACONAZOLE; MALE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874386385     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-314     Document Type: Article

References (34)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
2. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
3. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for meta-static castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147-1154.
4. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
5. Nilsson S, Franzén L, Parker C et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587-594.
6. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.
7. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011;364:2055-2058.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-674.
9. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22:151-185.
10. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007;448:645-646.
11. Kluetz PG, Figg WD, Dahut WL. Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother 2010;11:233-247.
12. Chong CR, Xu J, Lu J et al. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2007;2:263-270.
13. Aftab BT, Dobromilskaya I, Liu JO et al. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer. Cancer Res 2011;71: 6764-6772.
14. Xu J, Dang Y, Ren YR et al. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A 2010;107: 4764-4769.
15. Karhadkar SS, Bova GS, Abdallah N et al. Hedgehog signaling in prostate regeneration, neo-plasia and metastasis. Nature 2004;431:707-712.
16. Kim J, Tang JY, Gong R et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010;17:388-399.
17. Janssen-Ortho, Inc. Itraconazole prescribing information, 2001. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020083s040s041s044lbl.pdf, Accessed December 12, 2012.
18. Pili R, Häggman M, Stadler WM et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 2011;29:4022-4028.
19. Tzelepi V, Karlou M, Wen S et al. Expression of Hedgehog pathway components in prostate carcinoma microenvironment: Shifting the balance towards autocrine signaling. Histopathology 2011;58: 1037-1047.
20. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26: 1148-1159.
21. Morris MJ, Basch EM, Wilding G et al. Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research. Clin Genitourin Cancer 2009;7: 51-57.
22. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
23. Shaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:2023-2029.
24. Seifert AW, Zheng Z, Ormerod BK et al. Sonic hedgehog controls growth of external genitalia by regulating cell cycle kinetics. Nat Commun 2010;1:1-9.
25. Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959-1966.
26. LoRusso PM, Rudin CM, Reddy JC et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-2511.
27. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 2012 [Epub ahead of print].
28. Trump DL, Havlin KH, Messing EM et al. High-dose ketoconazole in advanced hormone-refractory prostate cancer: Endocrinologic and clinical effects. J Clin Oncol 1989;7:1093-1098.
29. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-1033.
30. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
31. Yu EM, Jain M, Aragon-Ching JB. Angiogenesis inhibitors in prostate cancer therapy. Discov Med 2010;10:521-530.
32. Tomaschitz A, Pilz S, Ritz E et al. Aldosterone and arterial hypertension. Nat Rev Endocrinol 2010; 6:83-93.
33. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-4571.
34. Bolland MJ, Bagg W, Thomas MG et al. Cushing's syndrome due to interaction between corticosteroids and itraconazole. Ann Pharmacother 2004;38:46-49.